Compare Eli Lilly And Co (LLY) vs Realty Income Corp (O) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Realty Income (O) trades at $65.04, down 1.02% today, near the analyst consensus price target of $67.50. The stock shows a bullish technical setup with strong moving average signals, though RSI levels suggest mild overbought conditions. Recent earnings have missed expectations for three consecutive quarters, but revenue growth remains steady, rising to $5.75B in 2025. The company maintains a high dividend yield with consistent payouts, supported by robust operating cash flow of $4.0B.

Outlook is cautiously optimistic with a solid dividend profile and expansion through partnerships, but elevated P/E of 53.86 and recent earnings misses pose valuation and execution risks. Debt levels have increased, with debt-to-asset ratio reaching 39.93% in 2025, adding financial leverage concerns. Analyst sentiment is mixed with 41% buy ratings, reflecting balanced views on growth potential versus rich valuations.